Eby George A
George Eby Research, 14909-C Fitzhugh Road, Austin, TX 78736, USA.
Med Hypotheses. 2005;64(6):1124-6. doi: 10.1016/j.mehy.2004.12.019.
Low blood levels of zinc are often noted in acute lymphocytic leukemia (ALL), but zinc is not administered as part of any modern chemotherapy program in the treatment of ALL. Upon noting low blood levels of zinc in a 3-year-old 11.3 kg girl, zinc at the rate of 3.18 mg/kg body weight/day was administered from the start of chemotherapy through the full 3 years of maintenance therapy. Dosage was split with 18 mg given at breakfast and 18 mg zinc with supper. The result was a bone marrow remission from 95+% blast cells to an observed zero blast cell count in both hips within the first 14 days of treatment which never relapsed. In addition to the reduction of blast cells to an observed count of zero (not a single leukemic or normal blast), red blood cell production and other hemopoietic functions returned to normal at a clinically remarkable rate. There were no side effects from zinc or chemotherapy at any time, and zinc is hypothesized to have improved the patient's overall ability to withstand toxic effects of chemotherapy. This report identifies zinc treatment as being vital to rapid and permanent recovery from ALL. The extremely broad role of zinc in pre-leukemic adverse health conditions, viral, fungal and tumoral immunity, hemopoietics, cell growth, division and differentiation, genetics and chemotherapy interactions are considered. If a nutrient such as zinc could be shown to strengthen the function of chemotherapy and immune function, then it could be hypothesized that the relapse rate would be lessened since the relapse rate is related to both the rate at which a remission is obtained and the thoroughness of the elimination of leukemic blasts. Identical results also occurred in 13 other children with ALL whose parents chose to treat with zinc adjuvant. Since treatment with zinc and other identified deficient nutrients, particularly magnesium, did not appear injurious in ALL and they appear to be highly beneficial, controlled clinical studies of zinc (3.18 mg/kg body weight/day) with magnesium (8.0 mg/kg body weight/day) as adjuvants to chemotherapy in the treatment of childhood ALL are suggested. Treatment with zinc adjuvant is hypothesized to accelerate recovery from ALL, and in conjunction with chemotherapy, cure ALL.
急性淋巴细胞白血病（ALL）患者常出现血锌水平降低的情况，但在ALL的现代化疗方案中并未将锌作为治疗的一部分。在一名3岁、体重11.3千克的女孩血锌水平降低后，从化疗开始直至整个3年维持治疗期间，均按照3.18毫克/千克体重/天的剂量给予锌。剂量分为早餐时服用18毫克和晚餐时服用18毫克锌。结果是在治疗的前14天内，骨髓中原始细胞从95%以上降至双髋部观察到的原始细胞计数为零，且从未复发。除了原始细胞减少至观察到的计数为零（没有一个白血病或正常原始细胞）外，红细胞生成和其他造血功能以临床上显著的速度恢复正常。在任何时候锌或化疗均未产生副作用，据推测锌提高了患者耐受化疗毒性作用的整体能力。本报告指出锌治疗对于ALL的快速和永久康复至关重要。锌在白血病前期不良健康状况、病毒、真菌和肿瘤免疫、造血、细胞生长、分裂和分化、遗传学以及化疗相互作用等方面具有极其广泛的作用。如果能证明像锌这样的营养素可增强化疗功能和免疫功能，那么可以推测复发率将会降低，因为复发率与缓解获得的速度以及白血病原始细胞清除的彻底程度均有关。其他13名ALL患儿的父母选择使用锌辅助治疗，也出现了相同的结果。由于用锌和其他已确定缺乏的营养素（特别是镁）进行治疗在ALL中似乎并无危害，而且似乎非常有益，因此建议对锌（3.18毫克/千克体重/天）与镁（8.0毫克/千克体重/天）作为儿童ALL化疗辅助剂进行对照临床研究。据推测，使用锌辅助治疗可加速ALL的康复，并与化疗相结合治愈ALL。
